We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

It’s not a coincidence that Pfizer, Lilly, Amgen, and AbbVie are all hawking anti-CGRP migraine drugs on their direct-to-consumer portals; these drugs don’t work well enough to be popular ...

Amgen Inc.'s Q3 earnings may not be a major upside, but new pipeline drugs and potential breakthroughs could drive growth.

Ozempic and Wegovy, made by Novo Nordisk, are now listed as available across all doses on the FDA’s drug shortage list. But ...

The biotech says it will launch its first drug with a monthly list price of around $19,700, in the same ballpark, but a little more than the $18,990 per month Amgen charges for Lumakras.

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.

The latest trends have been impressive. In the second quarter, Amgen's product net sales climbed by 20% year over year with 12 drugs posting at least double-digit sales growth. Some of the top ...

Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech’s drug pipeline.

Enbrel, one of Amgen's established products, faces challenges in the Medicare Part D negotiations, with a 67% discount to list price. While this impacts the drug's profitability, only about 25% of ...

Amgen Inc.'s stock took a hit Monday after the biotechnology giant lost a bull, amid concerns that prices already reflect investor optimism over the obesity drug candidate, leaving more downside ...

Enbrel, one of Amgen's established products, faces challenges in the Medicare Part D negotiations, with a 67% discount to list price. While this impacts the drug's profitability, only about 25% of ...